Evolving Roles of Transplant and Quadruplet Therapy in Multiple Myeloma
July 15th 2024During a Case-Based Roundtable® event, Adam D. Cohen, MD, discussed triplet vs quadruplet options for a patient with transplant eligible multiple myeloma and NCCN recommendations in the first article of a 2-part series.
Ide-cel Shows Efficacy Earlier in R/R Multiple Myeloma Despite Crossover
June 28th 2024During a Case-Based Roundtable® event, Surbhi Sidana, MD, discussed the KarMMa-3 trial of earlier-line CAR T-cell therapy in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Wirth Explores Challenges of Therapy Selection for RAI-Refractory Differentiated Thyroid Cancer
June 28th 2024During a Case-Based Roundtable® event, Lori J. Wirth, MD, discussed with participants how they approach use of lenvatinib and other therapy for patients with radioactive iodine–refractory differentiated thyroid cancer.
Zeidan Reviews Past Treatment Options for Patient With Lower-Risk MDS
June 27th 2024During a Case-Based Roundtable® event, Amer Zeidan, MBBS, discussed how he would have approached a patient with anemia from low-risk myelodysplastic syndrome before the development of newer drugs in the first article of a 2-part series.
Patient Considerations for Using Dual Immunotherapy for RCC
June 26th 2024During a Case-Based Roundtable® event, Nizar M. Tannir, MD, discussed the importance of site of metastasis and other factors in the use of nivolumab plus ipilimumab in renal cell carcinoma in the first article of a 2-part series.
CNS Activity of Third-Generation ALK TKIs Influence Approach in NSCLC
June 21st 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed with participants how they select treatment for a patient with ALK+ non–small cell lung cancer and brain metastases in the first article of a 2-part series.
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Assessing The Rationale Behind Triplet Regimens in RRMM
June 14th 2024During a Case-Based Roundtable® event, Ariel Grajales-Cruz, MD, discussed the long-term results of the phase 3 IKEMA study that build the rationale for use of the triplet therapy isatuximab, carfilzomib, and dexamethasone, in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series.
The Field of Recurrent RCC Regimens Continues to Grow
June 12th 2024During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed regimens for recurrent metastatic clear cell renal cell carcinoma including lenvatinib plus everolimus, belzutifan, and investigational cell therapy and bispecific agents in the second article of a 2-part series.
Birrer Assesses Tolerability Factors in Use of Lenvatinib/Pembrolizumab for Endometrial Cancer
June 11th 2024During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion focusing on dosing and tolerability issues in treating patients with advanced endometrial cancer with lenvatinib plus pembrolizumab.
Subgroup and Toxicity Analyses Favor Zanubrutinib Vs Ibrutinib in CLL
June 10th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed subgroup analyses and adverse events from the ALPINE trial of zanubrutinib for a patient with relapsed/refractory chronic lymphocytic leukemia in the second article of a 2-part series.
Grajales-Cruz Interprets Data for Earlier- Line CAR T-Cell Therapy in R/R MM
June 8th 2024During a Case-Based Roundtable® event, Ariel F. Grajales-Cruz, MD, discussed data from the KarMMa-3 trial of idecabtagene vicleucel and real-world data on the CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Khouri Analyzes How Daratumumab-Based Quadruplet Therapy Achieves MRD States in Multiple Myeloma
June 7th 2024During a Case-Based Roundtable® event, Jack Khouri, MD, discussed data from the GRIFFIN, PERSEUS, and MASTER trials that investigated quadruplet therapy in patients with newly diagnosed multiple myeloma.